Baylor Institute for Immunology Research, INSERM U, Dallas, Texas 75204, USA.
Annu Rev Immunol. 2010;28:535-71. doi: 10.1146/annurev-immunol-030409-101221.
The past decade has seen an explosion in the use of DNA-based microarrays. These techniques permit assessment of RNA abundance on a genome-wide scale. Medical applications emerged in the field of cancer, with studies of both solid tumors and hematological malignancies leading to the development of tests that are now used to personalize therapeutic options. Microarrays have also been used to analyze the blood transcriptome in a wide range of diseases. In human autoimmune diseases, these studies are showing potential for identifying therapeutic targets as well as biomarkers for diagnosis, assessment of disease activity, and response to treatment. More quantitative and sensitive high-throughput RNA profiling methods are starting to be available and will be necessary for transcriptome analyses to become routine tests in the clinical setting. We expect this to crystallize within the coming decade, as these methods become part of the personalized medicine armamentarium.
过去十年，DNA 微阵列的应用呈爆炸式增长。这些技术可以在全基因组范围内评估 RNA 的丰度。医学应用出现在癌症领域，对实体瘤和血液恶性肿瘤的研究导致了现在用于个性化治疗选择的测试的发展。微阵列也被用于分析广泛疾病的血液转录组。在人类自身免疫性疾病中，这些研究显示出了鉴定治疗靶点以及诊断、疾病活动评估和治疗反应生物标志物的潜力。更定量和敏感的高通量 RNA 分析方法开始出现，并且对于转录组分析成为临床环境中的常规测试是必要的。我们预计这将在未来十年内实现，因为这些方法成为个性化医疗武器库的一部分。
